



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

September 10, 2025

Corporate Relationship Department
M/s. BSE Ltd.
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, September 10th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") NATCO Pharma Limited, through its wholly owned South African subsidiary, and Adcock Ingram Holdings Limited have issued a combined circular to shareholders of Adcock Ingram giving notice of a general meeting on Thursday, October 9, 2025 to approve the Scheme of Arrangement. The offer comprises all issued ordinary shares in Adcock Ingram, excluding those already held by NATCO Pharma and Bidvest Group Limited. As such, the Scheme can only be voted upon by the minority shareholders to whom the offer is being made. Bidvest and NATCO Pharma will not participate in the vote. The link for the combined circular is being placed here https://senspdf.jse.co.za/documents/SENS_20250909_S510315.pdf.

On July 23, 2025, NATCO Pharma submitted a firm intention cash offer of ZAR 75 per share to Adcock Ingram to acquire the minority-held shares in Adcock Ingram through scheme of arrangement. This will amount to an acquisition cost of around ZAR 4 billion or US\$ 228 million at the current prevailing exchange rate.

Should the offer be accepted, NATCO Pharma will hold a 35.75% stake in Adcock Ingram with Bidvest holding the remaining stake and Adcock Ingram will be delisted from the JSE. As a private company, Bidvest and Natco Pharma will seek new revenue streams and opportunities to expand the Company's footprint in one of the largest markets on the African continent.

Subject to the Scheme getting approved and fulfilment of other conditions, it is envisaged that Adcock Ingram will be delisted by 11 November 2025.

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE: NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH) and headquartered in Hyderabad, India. Established in 1981, Natco Pharma India has progressively developed into a diversified pharmaceutical manufacturer with a principal emphasis on research and development, manufacturing, and global marketing of both finished dosage formulations and active pharmaceutical ingredients. Natco Pharma India operates across various geographies (in over 50 countries), including emerging and developed markets, with a particular focus on delivering quality medicines in oncology, cardiology, neurology, and other high-value therapeutic categories.

Natco Pharma South Africa Proprietary Limited is a newly incorporated, wholly owned subsidiary of Natco Pharma India, established for the purpose of making the Offer to shareholders.

For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter)

NATCO Pharma Ltd

NATCO House

Road No.2, Banjara Hills

Hyderabad-500 034, India

About Adcock Ingram

Adcock Ingram is a South African pharmaceutical company established in 1891, and is ranked 2nd in the private and public pharmaceutical market in South Africa. The company manufactures, markets, and distributes healthcare products to both the private and public sectors of the market. Its portfolio includes an extensive range of Prescription, Over-the-counter (OTC), Consumer and Hospital products, manufactured in three facilities in South Africa and two in India. Its extensive portfolio of products includes well-known household brands such as Panado, Allergex, Epi-max, Citro-Soda, and Myprodol.

Adcock Ingram has a 10% market share of the private market, is the leader in the OTC pharmaceutical market, and is the largest supplier of hospital and critical care products in South Africa.

For further information please contact:

Rajeev Menon, Investor Relations

Rajesh Chebiyam, EVP - CHS

ir@natcopharma.co.in/investors@natcopharma.co.in